Zoetis (NYSE: ZTS) — Perfil da empresa, notícias e dados financeiros
Zoetis is a global animal health company specializing in veterinary medicines, vaccines, and diagnostic products.
Zoetis
Zoetis is a global animal health company focused on the discovery, development, manufacture, and commercialization of veterinary medicines, vaccines, diagnostics, and biopharmaceuticals. Operating across more than 100 countries, the company serves veterinarians, livestock producers, and pet owners with products designed to predict, prevent, detect, and treat animal diseases. Its product portfolio spans companion animals such as dogs, cats, and horses, as well as livestock species including cattle, swine, poultry, sheep, and aquaculture. Key product categories encompass parasiticides, anti-infectives, dermatology treatments, monoclonal antibodies, pain management therapies, and diagnostic instruments supported by automated platforms and data-driven solutions.
Resumo
Operações
Produtos e/ou serviços de Zoetis
- Companion Animal Parasiticides: Development and distribution of broad-spectrum oral, topical, and injectable formulations protecting dogs and cats against heartworms, ticks, fleas, roundworms, and hookworms across global veterinary clinics and retail distribution channels.
- Companion Animal Dermatology and Monoclonal Antibodies: Targeted therapeutic solutions including oral Janus kinase inhibitors and species-specific monoclonal antibody injections formulated to relieve allergic pruritus, atopic dermatitis, and osteoarthritis pain in canine and feline populations worldwide.
- Livestock Anti-Infectives and Biologicals: Production and supply of therapeutic antibiotics, vaccines, and medicated feed additives for cattle, swine, poultry, and sheep to treat respiratory and enteric illnesses, improving herd health across agricultural facilities internationally.
- Veterinary Diagnostics and Point-of-Care Platforms: Provision of automated benchtop diagnostic analyzers, rapid blood chemistry and hematology testing kits, reference laboratory services, and digital image processing tools enabling rapid disease detection in veterinary practices globally.
- Aquaculture Health Solutions: Specialized vaccines, therapeutic treatments, and aquatic health monitoring tools designed to prevent infectious pancreatic necrosis, sea lice infestations, and bacterial infections across commercial salmon and finfish farming operations.
- Animal Health Manufacturing and Supply: Global network of specialized manufacturing sites delivering large-scale fermentation, chemical synthesis, sterile liquid filling, and biological vaccine formulation to supply commercial markets and veterinary professionals across North America, Europe, Asia, and Latin America.
equipe executiva do Zoetis
- Kristin C. PeckCEO & Director
- Roxanne LaganoExecutive VP, General Counsel & Corporate Secretary
- Wetteny N. JosephSpecial Advisor to the CEO
- Robert J. PolzerScientific Advisor
- Jamie BrannanExecutive VP & Chief Commercial Officer
- James K. SaccaroExecutive VP, CFO & COO
- Keith SarbaughExecutive VP & Chief Digital and Technology Officer
- Steven FrankVice President of Investor Relations
- Julie A. FullerExecutive VP, Chief Human Resources Officer & Global Operations
- Abhay U. NayakExecutive VP & President of U.S. Commercial Operations
Últimas notícias sobre a Zoetis
Histórico de dividendos
Dividendos por ação pagos pela Zoetis, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $2.1200 |
| FY2025 | — | — | — | $2.0000 |
| FY2024 | — | — | — | $1.7280 |
| FY2023 | — | — | — | $1.5000 |
| FY2022 | — | — | — | $1.3000 |
Principais indicadores financeiros
Resultados divulgados pela Zoetis, em USD.
- Cap. de mercado
- 32,3 bi
- Receita (TTM)
- 9,5 bi
- P/L
- 12.9
- LPA (diluído, TTM)
- 6.1
- Dividend yield
- 2.5%
- Margem de lucro
- 27.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 9,5 bi | 3,6 bi | 2,7 bi | |
| 9,3 bi | 3,4 bi | 2,5 bi | |
| 8,5 bi | 3,1 bi | 2,3 bi | |
| 8,1 bi | 2,9 bi | 2,1 bi |